AOD9604 Fat-Loss Peptide: 2026 Research Guide

AOD9604 is a synthetic peptide fragment derived from human growth hormone (hGH), specifically the C-terminal region amino acids 177 to 191. Unlike full-length hGH, AOD9604 does not raise IGF-1, affect blood glucose, or stimulate bone growth. Its action is narrowly targeted: lipolysis, the breakdown of stored fat, without the systemic growth hormone side effect profile.

This guide is a working reference for laboratory and research use. It is not medical advice.

What AOD9604 Actually Is

AOD9604 was originally developed by Monash University and later licensed to Metabolic Pharmaceuticals for clinical trials. The peptide is a modified 15-amino-acid fragment of hGH with an additional tyrosine residue at the N-terminus to improve stability.

Key structural facts:

• •Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
• •Molecular weight: ~1,817 Da
• •Mechanism: Mimics the natural lipolytic domain of hGH without binding the GH receptor

Because it does not interact with the GH receptor, AOD9604 does not trigger:

• •IGF-1 elevation
• •Organ growth or acromegaly risk
• •Insulin resistance or blood glucose perturbation
• •Water retention or carpal tunnel syndrome

This clean side-effect profile is why it has been studied in obesity and metabolic research for over two decades.

The Mechanism, How It Burns Fat

AOD9604 works through two primary pathways:

1. Stimulation of Beta-3-Adrenergic Receptors

The peptide upregulates signaling in adipose tissue through beta-3-adrenergic receptors, which are predominantly expressed in brown and visceral fat. This increases lipolysis, the enzymatic breakdown of triglycerides into free fatty acids and glycerol, and raises resting metabolic rate in fat cells without affecting systemic metabolism. This mechanism was directly confirmed using beta(3)-adrenergic-receptor knockout mice, which lost AOD9604's lipolytic response while wild-type obese mice retained it.(1)

2. Inhibition of Lipogenesis

AOD9604 reduces the formation of new fat droplets (lipogenesis) in mature adipocytes. In cell culture studies, treated adipocytes showed a measurable decrease in fatty acid uptake and triglyceride storage.

The net effect is a one-way fat-loss signal: stored fat is mobilized and oxidized, while new fat deposition is suppressed. Importantly, this occurs without appetite suppression, a completely different mechanism from GLP-1 agonists like semaglutide.

Clinical Research, What the Trials Show

Phase 1/2 Obesity Trials (Metabolic Pharmaceuticals, 2000s)

• •AOD9604 was tested in oral and injectable forms for weight loss in obese subjects
• •Injectable protocols showed measurable reductions in body fat mass vs. placebo
• •Oral bioavailability was poor; subcutaneous injection became the standard research route
• •No significant adverse events were reported at therapeutic doses
• •The peptide was generally well tolerated with no impact on glucose, insulin, or IGF-1

Animal and In-Vitro Data

• •Rodent studies: AOD9604 reduced adipose tissue mass by 20 to 30 percent over 4 to 6 weeks vs. controls(1)
• •In-vitro adipocyte models: decreased lipid accumulation and increased hormone-sensitive lipase activity
• •No effect on lean body mass in any published model, fat-specific action confirmed

Regulatory Status

AOD9604 has not received FDA approval for human use. It was investigated as a therapeutic but development stalled for commercial, not safety, reasons. It remains widely available as a research peptide for laboratory use.

Research Parameters in the Published Literature

Published trial and preclinical data on AOD9604 generally falls within a defined range for subcutaneous administration in study models, with published dose-response data suggesting fat-loss outcomes do not scale proportionally beyond the lower-to-mid portion of the studied range, the best risk-to-benefit ratio in the available data sits toward the lower end rather than the upper end of the range tested. Consult the primary trial literature (Metabolic Pharmaceuticals' published Phase 1/2 data) for exact study parameters rather than relying on secondary summaries.

AOD9604 vs. GH Fragment 176-191, The Confusion Cleared

These two peptides are often conflated because both are hGH fragments with fat-loss properties. They are not the same compound.

In practice, both peptides are used for the same research endpoint, targeted fat loss without systemic GH effects, and many researchers consider them functionally equivalent at the protocol level. AOD9604 has the larger published human data set.

Side Effects and Safety

AOD9604's side effect profile is notably clean:

• •No hypoglycemia (unlike some metabolic peptides)
• •No water retention (unlike full GH or GHRPs)
• •No joint pain or carpal tunnel (unlike IGF-1 or GH)
• •No appetite suppression (unlike GLP-1s)
• •No impact on sleep architecture (unlike Ipamorelin/CJC stacks)

Reported mild events in research contexts:

• •Transient injection-site redness or itching
• •Mild headache in the first 48 to 72 hours
• •Increased body temperature or sweating during fasted cardio protocols

The peptide does not appear to have documented tolerance, dependence, or withdrawal.

Stacking in Research Contexts

AOD9604 is often paired with:

• •Ipamorelin + CJC-1295 no-DAC for body recomposition (fat loss + lean mass preservation)
• •5-Amino-1MQ for NAD+ pathway synergy and metabolic rate support
• •BPC-157 during cutting phases to protect joints under heavier training loads
• •Low-dose T3 or T4 thyroid support in advanced metabolic research protocols
• •Semaglutide or Tirzepatide for combined appetite suppression + fat oxidation (caution: stack complexity increases)

These are documented combinations in research literature, not clinical recommendations.

Sourcing, How to Verify Real AOD9604

AOD9604 is a short peptide (15 amino acids) and relatively easy to synthesize, which means the market is flooded with underdosed or mislabeled material.

What to demand:

1. HPLC purity at or above 98 percent at 220 nm, request the actual chromatogram
2. Mass spectrometry confirmation matching the theoretical mass of ~1,817 Da
3. Net peptide content at or above 90 percent
4. Lyophilized powder in sealed vials, not pre-mixed liquid
5. Cold-chain shipping with temperature verification
6. Lot-to-lot consistency, purity should not vary more than 1 percent between batches

A properly synthesized AOD9604 vial reconstitutes as a clear, colorless solution. Cloudiness or particles indicate degradation or poor synthesis.

At Enlife Peptides, every AOD9604 order ships with per-lot HPLC and MS documentation available on request, cold-chain dispatched to US, UK, AU and IN.

Storage and Reconstitution

• •Lyophilized: 24+ months at minus 20 C, 12 months at 2 to 8 C
• •Reconstituted: 28 days at 2 to 8 C in bacteriostatic water
• •Do not freeze-thaw reconstituted solution, activity degrades rapidly

See our peptide storage and handling guide for the complete protocol.

Frequently Asked Questions

Is AOD9604 the same as HGH?

No. AOD9604 is a 15-amino-acid fragment of hGH. It retains only the fat-metabolism signaling domain and does not bind the growth hormone receptor or raise IGF-1.

Does AOD9604 suppress appetite?

No. Unlike GLP-1 peptides, AOD9604 does not act on central appetite circuits. Fat loss occurs through direct adipose tissue signaling, not reduced food intake.

How long until fat loss is visible in research?

Most protocols report measurable changes in body composition after 3 to 4 weeks of daily dosing, with more pronounced effects at 6 to 8 weeks.

What does the literature say about long-term administration?

There is no published data on continuous year-round use, and receptor desensitization is theoretically possible, which is why published research designs generally study intermittent rather than continuous administration schedules. This article does not provide an administration protocol; consult the primary literature and institutional research protocols directly.

Is AOD9604 detectable in drug testing?

AOD9604 is not on standard WADA or sports anti-doping panels as of 2026, but peptide detection methodology is advancing. Researchers in competitive sport contexts should verify current regulations.

AOD9604 vs. GLP-1 for fat loss, which is better?

They are mechanistically different. GLP-1s (semaglutide, tirzepatide) reduce food intake and slow gastric emptying. AOD9604 directly increases fat oxidation without appetite change. For research programs comparing metabolic pathways, both compounds have distinct value.

What purity should I look for?

98 percent or higher HPLC-verified, with mass spectrometry confirmation on the batch COA.

Bottom Line

AOD9604 is the most validated non-GLP-1 fat-loss peptide in the research catalog. It offers a unique mechanism, direct adipose lipolysis without appetite suppression, glucose disruption, or GH-axis side effects, that makes it a valuable tool in metabolic research programs. The clinical safety data is stronger than for most research peptides, and the dosing protocol is simple and well established.

For a complete weight-loss research stack, AOD9604 pairs cleanly with GLP-1 compounds, growth hormone secretagogues, or mitochondrial peptides like MOTS-c. For pure, HPLC-verified AOD9604 with full documentation, browse our research catalog.

References

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. PMID: 11713213.

For research and laboratory use only. Not for human consumption.